VBI Vaccines Revenue and Competitors
Estimated Revenue & Valuation
- VBI Vaccines's estimated annual revenue is currently $15.7M per year.
- VBI Vaccines's estimated revenue per employee is $155,000
- VBI Vaccines's total funding is $380.7M.
Employee Data
- VBI Vaccines has 101 Employees.
- VBI Vaccines grew their employee count by -16% last year.
VBI Vaccines's People
Name | Title | Email/Phone |
---|---|---|
1 | President & CEO | Reveal Email/Phone |
2 | Chief Financial Officer & Head Corporate Development | Reveal Email/Phone |
3 | VP - Market Access & Contract Operations | Reveal Email/Phone |
4 | SVP Business Development | Reveal Email/Phone |
5 | VP For Immunization Policy, Government Affairs, and Advocacy | Reveal Email/Phone |
6 | Head EU Commercial Operations | Reveal Email/Phone |
7 | Director, Biologics CMC and Analytical Development | Reveal Email/Phone |
8 | Executive Assistant and Office Manager | Reveal Email/Phone |
9 | Manager, Quality Assurance | Reveal Email/Phone |
10 | Enterprise IT Manager | Reveal Email/Phone |
VBI Vaccines Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is VBI Vaccines?
VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B with the only 3-antigen hepatitis B vaccine, Sci-B-Vac®, which is approved for use and commercially available in Israel, and recently completed its Phase 3 program in the U.S., Europe, and Canada, and with an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI's enveloped virus-like particle (eVLP) platform technology enables development of eVLPs that closely mimic the target virus to elicit a potent immune response. VBI's lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma (GBM), a prophylactic cytomegalovirus (CMV) vaccine candidate, and a prophylactic pan-coronavirus vaccine candidate. VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel. To learn more, visit: www.vbivaccines.com News and Insights: www.vbivaccines.com/wire/ Investors: www.vbivaccines.com/investors/ Job Opportunities: www.vbivaccines.com/about/careers/
keywords:N/A$380.7M
Total Funding
101
Number of Employees
$15.7M
Revenue (est)
-16%
Employee Growth %
N/A
Valuation
N/A
Accelerator
VBI Vaccines News
Overall market sentiment has been down on VBI Vaccines Inc (VBIV) stock lately. VBIV receives a Bearish rating from InvestorsObserver Stock...
Pre-clinical research from VBI Vaccines has demonstrated an encouraging ability to boost and broaden the immune response against the...
Through its innovative approach to virus-like particles (VLPs), including a proprietary enveloped VLP (eVLP) platform technology, VBI...
VBI Vaccines Announces Third Quarter 2021 Financial Results and Provides Corporate Update - Hepatitis B (HBV) : ● Prophylactic : FDA and EMA regulatory review of VBI's 3-antigen prophylactic HBV vaccine candidate ongoing - U.S. PDUFA target action date November 30, 2021 ● On November 3, t ...
VBI Vaccines Announces e-Poster Presentation of 3-Antigen Prophylactic Hepatitis B Vaccine Data at The Liver Meeting® 2021 CAMBRIDGE, Mass. (November 1, 2021) - VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and tr ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $22M | 101 | 1% | $478.3M |
#2 | $15.7M | 101 | 63% | $203M |
#3 | $14.6M | 101 | 6% | $28.8M |
#4 | $15.7M | 101 | -6% | N/A |
#5 | $23.9M | 102 | -3% | N/A |